Cancer BiologybioRxivPreprint
A Novel CREBBP/p300 Activator, YF2, Enhances Cytotoxic and Immune-Mediated Responses in B-Cell Lymphoma
Ted B. Piorczynski, Yuxuan Liu, Brian Estrella…·Jennifer Effie Amengual
This paper evaluates YF2, a CREBBP/p300 activator, showing it enhances cytotoxicity and immune responses in B-cell lymphoma by restoring acetylation and altering the immune microenvironment.
DOI 10.1101/2025.03.13.642871